In addition, an extension of the approval period is required for the active substances aluminium ammonium sulphate, cymoxanil, dimethomorph, ethephon, fluoxastrobin, folpet, formetanate, gibberellic acid, gibberellins, metribuzin, milbemectin, phenmedipham, pirimiphos-methyl, propamocarb, prothioconazole and S-metolachlor to provide the time necessary to carry out an assessment as regards the potential endocrine disrupting properties of those active substances in accordance with the procedure set out in Articles 13 and 14 of Implementing Regulation (EU) No 844/2012.
Recital 6, Regulation (EU) 2022/708
In forcesince 5 May 2022
- celex=32012R0844